 |
|
| Updated Nov. 9, 2009 |
|
||||||||
 |
|
 |
|
 |
|
 |
|
 |
|
||||||||
| |
|
Case Challenges in Schizophrenia
ISSUE: NOVEMBER, 2008 Atypical antipsychotics have now been available in the United States for approximately 20 years. When these drugs first came out, they were hailed as a true breakthrough and the medical community had high hopes for the class. In general, the newer medications have not necessarily reached their promise of helping all patients control their symptoms of schizophrenia. read more & comment | |
|
Reassessing ADHD Symptom Control in Children With ADHD
ISSUE: AUGUST, 2008 Reassessment at back-to-school time is very important. The demands on children during a typical summer vacation generally are much fewer than those associated with being back at school. read more & comment | |
|
Vyvanse™ Analog Classroom Studies in Children With ADHD
ISSUE: JULY, 2008 Attention-deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric disorders of childhood, with approximately 7.8% of school-aged children being diagnosed with the disorder at some point in their lives, according to a Centers for Disease Control and Prevention survey. Symptoms of inattention, hyperactivity, and impulsivity may compromise multiple domains of a child’s life, including impaired cognition, poor psychosocial functioning, and academic underachievement, thereby impacting not only the child but the family as well. read more & comment | |
|
Vyvanse™:The First Prodrug for Attention-Deficit/Hyperactivity Disorder
ISSUE: APRIL, 2008 Attention-deficit/hyperactivity disorder (ADHD) affects approximately 7.8% of school-aged children who have been diagnosed with ADHD at some point in their lives, according to a Centers for Disease Control and Prevention survey. read more & comment |
| |
| MOREBENCH TO BEDSIDE | |
| |
| No more articles availalble | |
 Bench to Bedside Archives |
| home | about us | advertise | contact | publications |